CLARITIN-D
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLARITIN-D (CLARITIN-D).
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
| Metabolism | Loratadine is extensively metabolized in the liver via CYP3A4 and CYP2D6 to its active metabolite descarboethoxyloratadine. Pseudoephedrine is partially metabolized in the liver by N-demethylation and undergoes renal excretion. |
| Excretion | Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary. |
| Half-life | Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine. |
| Protein binding | Loratadine: 97-99% (albumin, alpha-1-acid glycoprotein); desloratadine: 82-87%; pseudoephedrine: negligible (<5%). |
| Volume of Distribution | Loratadine: 120 L/kg (extensive tissue distribution); desloratadine: 15-20 L/kg; pseudoephedrine: 2-3 L/kg (distributes into body water). |
| Bioavailability | Loratadine: ~40% (high first-pass metabolism); pseudoephedrine: ~100% (oral); desloratadine: ~40-50% (oral). |
| Onset of Action | Loratadine: 1-3 h oral; pseudoephedrine: 0.5-1 h oral. |
| Duration of Action | Loratadine: 24+ h; pseudoephedrine: 4-6 h (immediate-release) or 12 h (extended-release). Clinical effect: antihistaminic up to 24 h, decongestant up to 12 h. |
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For GFR 30-50 mL/min: administer every 24 hours. For GFR <30 mL/min: contraindicated due to risk of pseudoephedrine accumulation. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: administer every 24 hours or consider alternative therapy. |
| Pediatric use | Children <12 years: not recommended due to fixed-dose combination. Children ≥12 years: same as adult dose. |
| Geriatric use | Elderly patients (≥65 years): use with caution due to increased sensitivity to pseudoephedrine (e.g., CNS stimulation, hypertension); consider starting with lower dose or alternative therapy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLARITIN-D (CLARITIN-D).
| Breastfeeding | Loratadine (antihistamine) and pseudoephedrine (decongestant) both excreted in breast milk. M/P ratio for loratadine is approximately 1.1; pseudoephedrine M/P ratio is approximately 2.6. Potential for irritability and decreased milk supply due to pseudoephedrine. Use with caution, preferably immediate-release loratadine alone. |
| Teratogenic Risk | First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimester: Risk of premature labor, low birth weight, and neonatal withdrawal with chronic high-dose decongestant use. |
■ FDA Black Box Warning
Not available.
| Serious Effects |
Hypersensitivity to loratadine, pseudoephedrine, or any component; narrow-angle glaucoma; severe hypertension; severe coronary artery disease; concurrent use or recent use of MAOIs (within 14 days); urinary retention; patients with severe hepatic impairment.
| Precautions | Severe hypertension or coronary artery disease; increased intraocular pressure; glaucoma; prostatic hypertrophy; diabetes mellitus; thyroid disease; use in patients with renal or hepatic impairment; avoid use with MAOIs or within 14 days of stopping MAOIs; risk of cardiovascular events including stroke and arrhythmias. |
| Food/Dietary | Avoid concurrent consumption of alcohol or caffeine-containing beverages (coffee, tea, cola) as they may exacerbate stimulant effects. Taking with food may reduce gastrointestinal irritation. Avoid high-tyramine foods (aged cheese, cured meats) if also taking MAOIs (contraindicated due to hypertensive crisis risk). |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure (risk of pseudoephedrine-induced hypertension). Assess fetal growth and amniotic fluid volume if used chronically in second/third trimester. Monitor for neonatal adverse effects (irritability, poor feeding) if used near term. |
| Fertility Effects | Limited data; pseudoephedrine may theoretically impair uterine blood flow; no established impact on fertility. Loratadine is not associated with fertility impairment. |
| Clinical Pearls | CLARITIN-D combines loratadine (antihistamine) and pseudoephedrine (decongestant). Use with caution in hypertension, hyperthyroidism, and prostate hypertrophy. Avoid in severe coronary artery disease. Monitor for insomnia and nervousness. Onset of action within 1-3 hours, duration 12 hours. Extended-release formulation must not be crushed or chewed. |
| Patient Advice | Take exactly as directed; do not exceed 2 tablets in 24 hours. · Swallow whole; do not crush or chew extended-release tablets. · Avoid alcohol; may increase drowsiness or dizziness. · Contact your doctor if symptoms persist beyond 7 days or with fever. · Do not use with other decongestants or antihistamines without consulting a physician. · May cause insomnia; take last dose at least 4-6 hours before bedtime. · Inform your doctor if you have high blood pressure, heart disease, or prostate issues. |